iTeos Therapeutics has been saved
Helping a young local biotech succeed globally
iTeos Therapeutics develops immunotherapies solutions: groundbreaking treatments using the immune system to fight cancer. To support large ambitions and significant market potential, a biotech company requires good advice. iTeos Therapeutics chose Deloitte Audit.
Based in Gosselies, Belgium, iTeos Therapeutics has around 40 employees and a fast growing revenue. Yet to become a world-class leader, it faces the same challenges as big companies.
Why did iTeos Therapeutics opt for Deloitte? First, they recognised our expertise in the biotech field. Second was the Audit team’s ability to take innovative approaches to managing the audit process pragmatically to fit with their current context. Finally, iTeos Therapeutics also knew that Deloitte’s multidisciplinary capabilities would facilitate the Audit team’s interactions with all stakeholders.
Our aim is to focus on companies with strong potential and help them achieve success in every step of their growth path.
Julie Delforge, Partner, Audit
Transparency and confidence
Deloitte’s global network was another important factor for the company. It would allow iTeos Therapeutics to interact with potential partners anywhere in the world. A final strong point was Deloitte’s reputation and expertise in helping companies assure transparency and confidence, qualities that are part of the iTeos Therapeutics’ DNA.
Once the mandate began, the Audit team started providing advice on technical matters. The collaborative chemistry has been excellent. Deloitte has shown flexibility in working with the company’s existing auditor and in adapting to the specific needs of iTeos Therapeutics. Deloitte Partner Julie Delforge explains, “Our aim is to focus on companies with strong potential and help them achieve success in every step of their growth path.”
The success of iTeos will be built on the strengths of its stakeholders: Deloitte combines global expertise with in-depth knowledge of biotech challenges.
Michel Detheux, CEO iTeos Therapeutics